Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHaferlach, Claudia
dc.contributor.authorMeggendorfer, Manja
dc.contributor.authorBarba Suñol, Pere
dc.contributor.authorMorgades, Mireia
dc.contributor.authorGenescà, Eulàlia
dc.contributor.authorGonzález Gil, Celia
dc.contributor.authorFuster-Tormo, Francisco
dc.date.accessioned2022-06-14T07:29:05Z
dc.date.available2022-06-14T07:29:05Z
dc.date.issued2021-10
dc.identifier.citationGenescà E, Morgades M, González-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, et al. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leuk Res. 2021 Oct;109:106612.
dc.identifier.issn0145-2126
dc.identifier.urihttps://hdl.handle.net/11351/7676
dc.descriptionCytogenetics; Prognosis; Therapy
dc.description.abstractThe potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesLeukemia Research;109
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectLeucèmia limfoblàstica - Prognosi
dc.subjectAnomalies cromosòmiques
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshPrognosis
dc.subject.meshChromosome Aberrations
dc.titleAdverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.leukres.2021.106612
dc.subject.decsleucemia-linfoma linfoblástico de células precursoras
dc.subject.decspronóstico
dc.subject.decsaberraciones cromosómicas
dc.relation.publishversionhttps://doi.org/10.1016/j.leukres.2021.106612
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Genescà E, González-Gil C, Fuster-Tormo F] Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. [Morgades M] Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain. [Haferlach C, Meggendorfer M] MLL Munich Leukemia Laboratory, Munich, Germany. [Barba P] Servei d’Hematologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34139642
dc.identifier.wos000696732800016
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record